Bi-functional shRNA for Stathmin 1 Knockdown via Dual RISC Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in effectively targeting and reducing the expression of Stathmin 1 (STMN1), a protein overexpressed in various cancers, which contributes to cancer cell growth and metastasis.
Innovation Solution
Development of bi-functional short hairpin RNA (shRNA) designs that target the Stathmin 1 gene, utilizing both cleavage-dependent and cleavage-independent RNA-induced silencing complexes to knockdown STMN1 expression, delivered via compacted DNA nanoparticles encapsulated in liposomes for enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional RNA interference expression cassettes are used to target Stathmin 1, then some reduction in STMN1 expression is achieved, but the efficacy is insufficient to effectively inhibit cancer cell growth and metastasis
Solution Approach 1:
The invention divides the RNA interference mechanism into two distinct pathways: cleavage-dependent RISC (targeting mRNA for degradation) and cleavage-independent RISC (targeting mRNA for translational repression). By segmenting the approach into multiple mechanistic pathways, the invention achieves more comprehensive and effective STMN1 knockdown compared to conventional single-pathway approaches.
Solution Approach 2:
The bi-functional shRNA design enables a single RNA molecule to activate both cleavage-dependent and cleavage-independent RISC pathways simultaneously. This multi-functionality allows the same therapeutic agent to operate through multiple mechanisms, enhancing overall efficacy in inhibiting cancer cell growth and metastasis while targeting STMN1 expression.
2Device complexity
If single-pathway RNA interference is used, then the mechanism is simpler, but the therapeutic effect on cancer cell proliferation and invasiveness is limited
Solution Approach 1:
The invention merges two previously separate RNA interference pathways (cleavage-dependent and cleavage-independent) into a single bi-functional shRNA molecule. This combination allows both mechanisms to work synergistically from one therapeutic agent, achieving enhanced anti-tumor activity without requiring multiple separate treatments.
Solution Approach 2:
The bi-functional shRNA can be delivered using composite delivery systems such as liposomes or nanoparticles that encapsulate the RNA molecule. These composite delivery vehicles protect the shRNA from degradation and enhance cellular uptake, thereby improving the reliability and efficacy of the therapeutic approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bi-functional shRNA effectively reduces STMN1 protein expression, inhibiting cancer cell growth, inducing apoptosis, and suppressing tumor cell proliferation and invasiveness, demonstrating significant anti-tumor activity in various cancer types.
Implementation Method 1
bifunctional RNA molecule that is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Stathmin 1
Implementation Method 2
delivered via compacted DNA nanoparticles encapsulated in liposomes for enhanced therapeutic efficacy
Data Source
AI summary
The present invention includes bifunctional shRNAs capable of reducing an expression of a Stathmin 1 gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Stathmin 1 gene, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Stathmin 1.